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Background. Pulmonary hypertension (PH) is a progressive fatal disease thus, noninvasive prognostic tools are needed to follow
these patients. The aim of our study was to evaluate fractional exhaled nitric oxide (FeNO) and exhaled breath temperature
(EBT) values in patients with PH from different causes and to correlate them with respiratory functional data. Methods. Twenty-
four PH patients underwent spirometry, carbon monoxide diffusion (DLCO) test, transthoracic echocardiography, right-heart
catheterization, and FeNO and EBT measurements. Results. We studied 3 groups according to the type of PH: 10 patients with
pulmonary arterial hypertension (PAH) (group A), 11 patients with PH due to chronic obstructive pulmonary disease (COPD)
(group B), and 3 patients with PH associated with left heart disease (group C). Mean FeNO values tend to be higher in group B
(15.0 ± 9.3ppb) compared with other groups (respectively, 9.9 ± 5.7 and 8.5 ± 5.2 ppb in groups A and C; p = 0.271) but no statistical
significance has been reached. Mean values of alveolar NO concentration (CANO) were higher in groups A and B compared to
group C (respectively, 16.9 ± 12.6; 13.9 ± 6.8; and 6.7 ± 2.0 ppb) (p = 0.045). EBT mean values were significantly lower in group
C when compared with other groups (group C: 29.0 +- 1.3∘C, groups A and B: 30.9 ± 1.3 and 31.2 ± 1.2∘C, respectively: p = 0.041).
EBT levels were inversely correlated to mean pulmonary artery pressure (PAPm) levels (Spearman coefficient -0.481; p = 0.017).
Conclusions. eNO, CANO, and EBT have been evaluated in three groups of PH patients. Interestingly EBT reduction was correlated
with PAPm increase, whereas FeNO was higher in COPD patients and CANO in PAH and COPD groups. Further studies are
needed to clarify EBT, FeNO, and CANO roles as biomarkers in the monitoring of patients with PH.
1. Background
Pulmonary hypertension (PH) is a disorder associated with
multiple clinical conditions; it is characterized by increased
vascular resistance and pressure overload of the right ventri-
cle. PH can be correlated to the majority of cardiovascular
and respiratory disorders in different stages of these diseases.
PH is defined as an increased mean pulmonary arterial
pressure (PAPm)≥25mmHg at rest as assessed by right-heart
catheterization (RHC) [1].Themechanism leading to PH is an
imbalance between vasoconstrictors agents and vasodilators
such as nitric oxide (NO) in pulmonary circulation [2].
PH is a progressive fatal disease; thus, easy usable and
noninvasive prognostic tools are needed for the management
of the follow-up of these patients. NO is a strong vasodilator
agent and it is synthesized from L-arginine by NO synthase
located in different cells of the respiratory tract [3]. A part
of NO exhaled during breath flows throughout airways and
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it is detectable in the expired air as fractional exhaled NO
(FeNO). FeNO is usually used as a noninvasivemarker of lung
inflammation in asthma and other pulmonary diseases since
it has been observed that its concentration in the exhaled air
is related to the presence of eosinophilic infiltration of the
airways [4]. FeNO in patients with PH has been evaluated
in a limited number of studies [5–10] with very different
results.The alveolar contribution to the exhaledNO (CANO)
can be estimated by an extended NO analysis [11]. This has
been widely applied in a variety of lung diseases and also in
patients with PH founding increased alveolar NO concen-
trations probably reflecting dysfunctional alveolocapillary
diffusion [12]. Other biomarkers in the exhaled air have been
determined and among them the exhaled breath temperature
(EBT) achieved great interest [13]. Whereas mucosal blood
flow is the major contributor to airway temperature, EBT
has been used as a marker of inflammation and airway
vascularization especially in patients with asthma [14] and
COPD [15]. Although the clinical use of this parameter is
still uncertain, this measurement is now validated and clear
reference limits in healthy subjects have been determined
[16].
The aim of this study is to describe FeNO, EBT, and
functional test data of the study population. The secondary
endpoint is to look for a correlation between FeNO, CANO,
and EBT values and pulmonary and cardiac functional data
in a group of patients affected by different causes of PH.
2. Patients and Methods
2.1. Patients. We conducted a cross-sectional, observational
study including patients with PH in follow-up at the Car-
diac Unit, University Hospital of Foggia. All participants
voluntarily signed the informed consent form.The study was
conducted in accordance with the principles of the Helsinki
Declaration and was approved by Local Ethic Institutional
Board (Approval Number 17/CE/2014).
Demographics, comorbid diseases, PH type, World
Health Organization (WHO) functional class status, and
right-heart catheterization findings assessed at the time of
diagnosis have been recorded. All patients underwent pul-
monary function tests, carbon monoxide diffusion (DLCO)
test, six-minute walking distance determination, transtho-
racic echocardiography, and FeNO and EBT levels determi-
nation. Exclusion criteria were smoking within the preceding
6 months, respiratory tract infection within the preceding 2
weeks, history of hyperreactive airways disease, pregnancy,
corticosteroid use with equivalent dose >10mg of prednisone
daily, and use of L-arginine, nitrates, or phosphodiesterase
inhibitors.
2.2. Pulmonary Function Tests. Static and dynamic lung
volumes were measured using the nitrogen washout method
and a pneumotachograph with volume integrator (CAD/Net
system 1070; Medical Graphics Corporation; St. Paul, MN)
in accordance with the criteria of the American Thoracic
Society (ATS) [17]. Lung carbon monoxide diffusion capac-
ity (DLCO) was assessed by means of the single-breath
method (PF/DX system;MedicalGraphicsCorporation)with
the patients in the sitting position [18]. The indexes were
expressed as percentages of the predicted normal.
2.3. Six Minutes Walking Distance. Walking capacity was
evaluated by means of the distance covered during a six-
minutewalking test (6MWD) according to theATS statement
[19]
2.4. Echocardiography. Conventional echocardiography was
used to assess left ventricular dimensions and ejection frac-
tion, peak velocities of trans-mitral early (E) and late diastolic
(A) LV filling, the ratio of trans-mitral early to late (E/A ratio)
left ventricular filling velocity, and E-deceleration time.
Pulmonary artery systolic pressures were estimated using
the approach of calculating the systolic pressure gradient
between right ventricle and right atrium by the maximum
velocity of the tricuspid regurgitant jet, using the modified
Bernoulli equation, and then adding to this value the esti-
mated right atrial pressures based on both the size of the
inferior vena cava and the change in calibre of this vessel
with respiration, according to international recommenda-
tions [20].
Transthoracic echocardiography was performed with the
use of iE33 (Philips Medical Systems, Andover, MA, USA).
All echocardiographic studies were performed and inter-
preted by experienced physicians. They were blinded of the
clinical data.
2.5. Right-Heart Catheterization. Hemodynamic assessment
was performed by right-heart catheterization (RHC), accord-
ing to recent guidelines [1]. Pulmonary arterial (systolic,
diastolic, and mean), right atrial, and pulmonary artery
wedge pressures (PAWP) were recorded at the end of a
quiet respiratory cycle. Oxygen saturations in the supe-
rior vena cava, inferior vena cava, pulmonary artery, and
femoral artery were obtained. Pulmonary vein saturation
was assumed at 98%. Pulmonary and systemic flows were
obtained by the Fick principle using table-derived oxygen
consumption values and calculated oxygen content at the
correspondent different sites. Pulmonary and systemic vas-
cular resistance indices were calculated using the standard
formula.
2.6. Exhaled Breath Temperature Measurement. EBT was
measured with X-halo device (Delmedica Investments, Sin-
gapore) according to previously validated methods [13].
Briefly, patients were requested to inhale freely through the
nose and then to exhale into the device at a rate and depth
typical of their normal tidal-breathing rhythm. Ambient
temperature was tested and recorded for each measurement
with an external thermometer.Wemeasured EBT to different
ambient temperature that ranged from 0 to 32∘C.
2.7. Measurement of Fractional Exhaled NO. Measurement
of FeNO was performed according to recent guidelines
(American Thoracic Society) [4, 21]. The Medisoft FeNO+
BioMed Research International 3
Table 1: Demographic characteristics of patients studied.
All Group A (PAH) Group B (COPD) Group C (HF) p
number of subjects 24 10 11 3
Age, years 63.2 ± 12.2 65 (11.2) 64.1 (14.4) 62.3 (10.5) 0.950
Male, n (%) 16 (66.6) 6 (60) 9 (81) 1 (33.3) 0.242
Bmi Kg/m2 27.2 ± 4.3 27.7 (5.1) 28.1 (3.4) 23.2 (1.7) 0.229
Smoking history, n (%) 5 (19.2) 0 5 (45.4) 0 <0.01
Pack-years 20.1 20.1
WHO functional class, n (%)
Class II 5 (20.8) 2 (20) 2 (18) 1 (33.3)
0.888Class III 17 (70.8) 8 (80) 7 (63.6) 2 (66.6)
Class IV 2 (8.4) 0 2 (18) 0
Co-morbid diseases, n (%)
Systemic Art. Hypertension 7 (26.9) 5 (50) 1 (9) 1 (33.3) 0.311
Diabetes mellitus 7 (26.9) 3 (30) 2 (18) 1 (33.3) 0.977
Ischemic Cardiac disease 4 (15.3) 1 (10) 1 (9) 2 (66.6) 0.999
Chronic renal failure 5 (19.2) 3 (30) 1 (9) 1 (33.3) 0.726
Data reported as mean ± standard deviation or frequencies.
PAH: pulmonary arterial hypertension; COPD: chronic obstructive pulmonary disease; HF: heart failure; WHO: World Health Organization; Art.: arterial;
n.s.: not significant; and p: p value among the groups studied (ANOVA or Chi square)
device, which is a semiportable for repeatable multiflowmea-
surement of exhaledNOwith offlinemeasurement, was used.
It has a software package that provides step-by-step online
quality control. The measurement range is 0–600 ppb [22].
FeNO was measured using a previously described restricted
breath technique, which employed expiratory resistance and
positive mouth pressure to close the velum and exclude nasal
NO: expiratory flow measurements at 50mL/s, 100mL/s,
and a 350mL/s have been evaluated. Repeated exhalations
were performed until three plateaus agreed within 5% of
interobservation difference. All the enrolled patients were
able to complete the measurements. The contributions of
the bronchi (bronchial NO flux) and the alveoli (alveolar
concentration of NO: CANO) to FeNO will be derived
from regression analysis, with NO output as the dependent
and exhalation flow rate as the independent factor. The
slope and intercept of the regression line are approximate
values of alveolar NO concentration and bronchial NO flux,
respectively [23].
2.8. Statistical Analysis. Statistical analysis has been per-
formed using SPSS 21.0 software (SPSS 21.0 for Windows;
SPSS, Chicago, Illinois). Descriptive statistics were reported
as mean, standard deviation (SD), median, and minimum-
maximum. Categorical variables were expressed as case
numbers and percentages. The normality of distribution
of variables was examined using Kolmogorov-Smirnov and
Shapiro-Wilk tests. Comparison between two variables was
assessed using the paired t-test or Wilcoxon test where
appropriated. Comparisons among more than two variables
were performed by ANOVA or Kruskal-Wallis test as appro-
priate. Comparisons of categorical variables were made using
the square 𝜒 test. Spearman correlation test was used to
examine the relationship between the variables. A p<0.05 was
considered as statistical significant.
3. Results
Demographic characteristics of the studied patients are
reported in Table 1. In total 24 patients were enrolled. Patients
were divided into 3 groups according to the classification of
PH adopted by European Society of Cardiology guidelines
[1]: group A was composed of 10 patients with pulmonary
arterial hypertension (PAH) (3 patients with idiopathic PH, 6
patients with PH secondary to connective tissue disease, and
1 patient with portal hypertension). Group B was composed
of 11 patients with PH secondary to chronic obstructive
pulmonary disease (COPD) (in accordance with GOLD
recommendations) [24]. Finally, data about 3 patients with
heart failure (HF) have been analysed as a separate group
(group C: PH associated with HF). Smoking history was
present in 5 patients (19.2%) (average 20.1 pack-years) and
all patients quit smoking before the study as established by
inclusion criteria of the study.
The whole cohort of patients had a moderate to severe
WHO functional class: five patients were in class II, 17 in
class III, and two in class IV. Patients were mostly men
(69.2%) with normal BMI (patients in the group C showed
a lower BMI compared to other groups as reported in
Table 1). Four patients showed chronic respiratory failure (all
of them included in group B). No patients had a documented
interstitial lung disease.The prevalences of comorbid diseases
are reported in Table 1.
The PAPm was 35.5 ± 8.3mmHg, mean pulmonary
capillary wedge pressure (PAWP) was 13.0 ± 4.6mmHg,
and pulmonary vascular resistance was 4.7 ± 2.2 wood
units (WU) at right-heart catheterization. PAPm was higher
in group C compared with the other two groups (data
reported in Table 2). Patients with PH associated with res-
piratory disease (COPD) had lower mean values of Tiffeneau
index (FEV
1
/FVC) compared with other groups (bronchial
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Table 3: FENO, CANO, and EBT data of all patients with pulmonary hypertension and compared among groups (ANOVA).
Mean(SD) Median (min-max)
All patients
FENO50 ppb 11.9 (7.6) 10 (2.2-27.6)
CANO ppb 14.1 (9.7) 12.6 (3-41)
EBT ∘C 30.7 (1.4) 30.9 (27.9 – 33.2)
Group A (PAH) Group B (COPD) Group C (HF) p
FENO50 9.9 (5.7) 15.0 (9.3) 8.5 (5.2)
10 (2.8-20.9) 11.8 (2.2-27.6) 8.0 (3.5-14) 0.271
CANO 16.9 (12.6) 13.9 (6.8) 6.7 (2.0)
12.6 (6-41) 13.0 (3-28) 6.3 (5-9) <0.045
EBT 30.9 (1.3) 31.2 (1.2) 29.0 (1.3) <0.041
30.9 (29.1-33.2) 31.4 (29.2-33.1) 28.5 (27.9-30.5)
Data reported as mean (standard deviation) and median (minimum-maximum).
FENO50: fractional exhaled nitric oxide at expiratory flow 50 ml/sec; CANO: alveolar concentration of nitric oxide; EBT: exhaled breath temperature; PAH:
pulmonary arterial hypertension; COPD: chronic obstructive pulmonary disease; n.s.: not significant; and p: p value among the groups studied (ANOVA).
obstruction pattern at pulmonary function tests). Patients
with PAH and with PH associated with COPD (groups A and
B) showed impaired DLCO (<70% predicted). Right-heart
catheterization and respiratory function data are represented
in Table 2. FeNO measurements have been completed by all
patients. Mean FeNO50 values were 11.9 ± 7.6 ppb in the
study population. These data conform to what is generally
considered the normal limits of FeNO (10.8 ± 47ppb) [25].
Mean CANO and EBT values were 14.1 ± 9.7 ppb and 30.7 ±
1-4∘C, respectively.
We recorded some interesting differences among the
different PH groups in the comparison between FeNO and
EBT values (results are reported in Table 3). Mean FeNO
values were higher in group B: 15.0 ± 9.3 ppb compared with
group 1 and group 3 (respectively, 9.9 ± 5.7 and 8.5 ± 5.2 ppb)
even if this trend was not statistically significant (p = 0.271,
Figure 1).
Mean values of CANO were higher in groups A and B
(16.9 ± 12.6; and 13.9 ± 6.8 ppb) compared with the values
observed in group C (6.7 ± 2.0 ppb) (p = 0.045 Figure 2).
We also found lower mean EBT values in the group C
(PH associated with HF) if compared with groups A and
B ones (30.9 ± 1.3∘C versus 30.6 ± 1.3 and 31.2 ± 1.2∘C,
respectively, p = 0.041 Figure 3). EBT levels were inversely
correlated to PAPm levels, with a Spearman coefficient of -
0.481; p = 0.0217 (Figure 4). On the other hand, FeNO and
CANO levels showed no correlation with any other vari-
able analysed or with comorbidities in the patients studied
groups.
4. Discussion
We conducted a cross-sectional, observational study on a
group of patients with PH, whose diagnosis was confirmed
by RHC, evaluating pulmonary function tests and FeNO and
EBT determination. This is one of the few studies directly
assessing RHC data and correlating with the respiratory
functional ones.
FE
N
O
50
(p
pb
)
p=0.271
Group A
(PAH)
Group B
(COPD)
Group C
(HF)
25
30
20
15
10
0
5
Figure 1: Boxplot showing FENO
50
(fractional exhaled nitric oxide
at 50ml/sec flow) values in the studied groups. Thick line showing
median, box showing 25% and 75% interquartile ranges, and error
bars showingminimum andmaximum values. Small circles indicate
outlier values. Groupswere compared byANOVA(PAH, pulmonary
artery hypertension; COPD, chronic obstructive pulmonary disease;
and HF, heart failure).
The main findings of this study were as follows: (i) FeNO
values were different between groups, even though nonstatis-
tically significant, with higher values observed in respiratory
group (group B) showing the presence of enhanced NO from
the large airways; (ii) CANO levels were higher in PAH and
respiratory groups (groups A and 2) probably reflecting the
reduced diffusion capacity from alveolar to vascular space
as demonstrated by the impaired DLCO observed in these
patients; and (iii) EBT was lower in group C showing an
inverse relationship with PAPm values.
The role of endogenous production of NO in PH up
to now is still uncertain and very controversial. Previous
published data demonstrated that FeNO levels are reduced
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p=0.045
p=0.02
0
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)
Figure 2: Boxplot showing CANO (alveolar concentration of nitric
oxide) values in the studied groups. Thick line showing median,
box showing 25% and 75% interquartile ranges, and error bars
showing minimum and maximum values. Small circles indicate
outlier values. Groupswere compared byANOVAandWilcoxon test
(PAH, pulmonary artery hypertension; COPD, chronic obstructive
pulmonary disease; and HF, heart failure).
p=0.043
p=0.019
Group A
(PAH)
Group B
(COPD)
Group C
(HF)
EB
T 
(C
° )
34
32
30
28
Figure 3: Boxplot showing EBT (exhaled breath temperature) val-
ues in the studied groups. Thick line showing median, box showing
25% and 75% interquartile ranges, and error bars showing mini-
mum and maximum values. Groups were compared by ANOVA
and Wilcoxon test (PAH, pulmonary artery hypertension; COPD,
chronic obstructive pulmonary disease; and HF, heart failure).
or normal in patients with PH, even considering the different
classification groups of patients; [7, 26–28] some authors
found that FeNO levels are especially elevated when asso-
ciated with systemic sclerosis and interstitial lung diseases
(ILD) [29]. In summary, available literature data about
FeNO values in patients with PH describe reduced levels if
compared with normal subjects except in cases of airways or
PAPm (mmHg)
EB
T 
(C
°)
Spearman coefficient -0,481
p=0.017 
34
32
30
28
20 30 40 50 60 70 80
Figure 4: Scatterplot showing correlation between EBT (exhaled
breath temperature) and PAPm (mean pulmonary arterial pressure)
in the studied patients (whole group).
alveolar inflammation. The underlying mechanisms associ-
ated with these reduced levels of FeNO in PH patients may
include (I) the reduction of substrate for NO production as
demonstrable by the fact that L-arginine oral administration
increased NO levels in precapillary PH [30]; (II) reduced
NO production by endothelial NO synthase (eNOS), as in
idiopathic PAH the levels of dimethylarginine (a potent
eNOS inhibitor) are higher [31]; and (III) reduced pulmonary
expression of eNOS itself has been hypothesized in PAH too
[32]. Finally a reduced diffusion capacity of NO from alveolar
to vascular space due to pathological modifications of the
pulmonary tissue may support the reduced FeNO values in
PH patients. Probably our results are explained by the fact
that the underlying respiratory disease in group B induces
a certain degree of airway inflammation that supports the
(modest) production of bronchial NO, although within the
limits of normality [25].
An increase inCANOvalues has been already observed in
previous published papers [7, 9]; it was related to the presence
of a preserved alveolar synthesis of NO in presence of a
reduced alveolar vascular-diffusion due to tissue pathological
alterations. Our results are in line with these data as we
observed reducedDLCO levels in case of higher CANOones.
If we consider the previous literature CANO normal levels
ranging about 1.8 ± 0.2 ppb [7], the levels found in all the
groups of our cohort were higher and this could be probably
explained by the fact that all showed decrease DLCO values.
It is interesting to highlight that elevated CANO levels were
observed in PHpatients with involvement in local pulmonary
pathophysiology (IPAH, connective disease, COPD, etc.).
Our data confirmed that CANO levels were lower in types
of PH associated with heart failure.
To our best knowledge, this is the first study analysing
EBT in PH patients. Recently EBT normal levels have been
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established ranging about 30.66 C∘ measured at 22∘C in non-
smoking healthy subjects [16]. According to previous pub-
lished data we confirmed that EBT was lower in patents with
more severe PH (as demonstrated by the inverse relationship
with PAPm).These data suggest that reduced EBT valuesmay
reflect a decreased bronchial vascularization due to vascular
degeneration in more advanced stages of PH, as the matter
of the fact that mucosal blood flow is the major contributor
to airway temperature. Literature data about EBT underline
a possible relationship between asthma inflammation and
airways remodelling too [33]. Moreover, in asthma elevated
rates of exhaled breath temperature changes and bronchial
blood flow have been related to increased vascularity of the
airway mucosa as a result of inflammation [34]. In the same
way, we may hypothesize that some mechanisms leading
to HP alteration of bronchial mucosal blood flow may be
revealed by the reduction of EBT when compared to normal
values, especially in patients with high levels of PAPm; this
may reflect the changes in bronchial blood flow and heat
exchange resulting in decreased bronchial vascularization.
A comparison of cardiac index values did not show any
significant difference among groups suggesting that blood
flow alterations should be localized only in bronchialmucosa.
According to our data, we observed a direct correlation
between 6MWD and EBT (spearman = 0.539 p = 0.021)
suggesting that low levels of EBT may predict the clinical
severity of PH in these patients
One of the possible limitations of the study is the
low number of subjects included, because PH types are
numerous and with different underlying diseases due to
equally different pathophysiological mechanisms. Therefore,
the study of homogenous group of patients with PH is
also difficult in relation to the relative rarity of the dis-
ease. In particular, the small number of patients with HF
enrolled in group 3 compels us to be extremely cautious
in generalizing the results of the study. Another possible
limitation could be the lack of data about airway inflamma-
tory cell patterns of the studied patients. These limitations
make difficult to establish whether patients enrolled with
COPD could be classified as overlap of asthma and COPD
(ACO); however, patients in group B had no history of
atopy or asthma or bronchial reversibility exceeding 12% or
200ml (which are major criteria for the diagnosis of ACO)
[35]
5. Conclusions
In summary our data show that the different biomarkers
evaluated in different groups of patients with PH could be in
relation to the pathophysiological nature of the disease. The
most original and interesting result is the association between
EBT reduction and PAPm increase. This relationship could
be due to an alteration of bronchial blood flow and reflects
the presence of a “remodelling” of airways structures in these
patients. These data, if confirmed by larger trials, open new
perspectives for future studies aimed at assessing a possible
role of FeNO, CANO, and particularly EBT as biomarkers in
PH and in the clinical monitoring of these patients.
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